Friday, November, 16, 2018 05:38:36

Category: Health

Akcea, Ionis attain FDA approval for hATTR treatment drug, Tegsedi™

Leading pharmaceutical conglomerate, Akcea Therapeutics and parent Ionis Pharmaceuticals Inc. have recently received approval for their hereditary transthyretin amyloidosis (hATTR) treatment drug, Tegsedi™ by the U.S. Food and Drug Administration (FDA). hATTR being a rare disease causes buildup of amyloid in the peripheral nervous system and …

Novartis announces FDA, EMA approval of SPMS drug, Siponimod

Swiss pharmaceutical conglomerate, Novartis International AG, has recently announced the acceptance of its secondary progressive multiple sclerosis (SPMS) treatment drug, Siponimod, by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The effects of multiple sclerosis (MS) can significantly impact lives, …

Pharma giant Merck opens M Lab™ Collaboration Center in Brazil

American pharmaceutical conglomerate, Merck & Co. has recently inaugurated a state-of-the-art M Lab™ Collaboration Center in São Paulo, Brazil, so as to serve customers in the Latin America region. Sources suggests that the center will effectively provide life science customers with a shared, exploratory environment, …

Enesi Pharma forms an R&D collaboration with Public Health England

Enesi Pharma, a UK-based pharmaceutical firm focused on manufacturing novel injectable solid-dose vaccines, has reportedly announced to have formed a research and development collaboration with Public Health England (PHE). As per trusted sources, the partnership would focus on developing and evaluating unique solid-dose formulations of …

Cobra Biologics with GE Healthcare and CPI to develop AAV vectors

Cobra Biologics, an international biologics and pharmaceuticals contract development and manufacturing organization recently announced that it will be collaborating with UK-based technology innovation foundation, Centre for Process Innovation (CPI) and GE Healthcare Life Sciences. The aim of the three-way partnership is to increase the strength …

Tris Pharma acquires NextWave Pharmaceuticals, expands ADHD portfolio

Tris Pharma, technology-based therapeutic products developer recently acquired NextWave Pharmaceuticals, a subsidiary of Pfizer, the American pharmaceutical corporation. The sum involved in the acquisition has not been disclosed. According to reliable sources, the acquisition will enable Tris Pharma to expand its product offering in the …